Current studies in patients with hematologic malignancies eligible for hospice
| Study ID . | Design . | Intervention . | Transfusion history of patient . | Primary outcome . | Results . |
|---|---|---|---|---|---|
| NCT04454723 | Single-arm pilot (n = 20 patients) | Symptom-triggered home transfusion support once weekly | Transfusion dependent | QOL, “palliative efficacy” (proportion improved after transfusion) | Interim analysis (n = 12): dyspnea improved by 55% and fatigue by 22% post-transfusion; mean QOL score increased; time in hospice increased to 11.5 days; all died at home43 |
| NCT05509439 | Single-arm feasibility (n = 10 patients, n = 10 caregivers) | Hospice-embedded home transfusion program | At least 1 RBC or platelet transfusion since blood cancer diagnosis | Feasibility (enrollment rate, completion of home transfusions, and patient-reported data) | n/a |
| NCT05063591 | Single-arm pilot (n = 20 patients) | Symptom-driven transfusion support hospice program once weekly | Transfusion dependent (requiring at least 2 units of blood products) | Feasibility (enrollment rate) | 45% enrollment rate (10 of 22 patients screened, and 4 screened patients died before consenting); length of stay on hospice was median 13 days (range 4-103); improved EOL outcomes, including all died outside the hospital (60% home, 40% inpatient hospice)42 |
| NCT04690205 | Single-arm pilot (n = 20) | Remote patient monitoring and home-based supportive care | n/a | Feasibility (enrollment rate, retention rate) | n/a |
| Study ID . | Design . | Intervention . | Transfusion history of patient . | Primary outcome . | Results . |
|---|---|---|---|---|---|
| NCT04454723 | Single-arm pilot (n = 20 patients) | Symptom-triggered home transfusion support once weekly | Transfusion dependent | QOL, “palliative efficacy” (proportion improved after transfusion) | Interim analysis (n = 12): dyspnea improved by 55% and fatigue by 22% post-transfusion; mean QOL score increased; time in hospice increased to 11.5 days; all died at home43 |
| NCT05509439 | Single-arm feasibility (n = 10 patients, n = 10 caregivers) | Hospice-embedded home transfusion program | At least 1 RBC or platelet transfusion since blood cancer diagnosis | Feasibility (enrollment rate, completion of home transfusions, and patient-reported data) | n/a |
| NCT05063591 | Single-arm pilot (n = 20 patients) | Symptom-driven transfusion support hospice program once weekly | Transfusion dependent (requiring at least 2 units of blood products) | Feasibility (enrollment rate) | 45% enrollment rate (10 of 22 patients screened, and 4 screened patients died before consenting); length of stay on hospice was median 13 days (range 4-103); improved EOL outcomes, including all died outside the hospital (60% home, 40% inpatient hospice)42 |
| NCT04690205 | Single-arm pilot (n = 20) | Remote patient monitoring and home-based supportive care | n/a | Feasibility (enrollment rate, retention rate) | n/a |
Life expectancy <6 months.
RBC, red blood cell.